The company, which was founded by scientists from the human field, managed to raise £8 million of Series A funding by February this year. It is now seeking further investment for an extension to that Series A funding by the autumn.
The company's Chief Scientific Officer is Professor Allan Bradley, Emeritus Director of the Wellcome Trust Sanger Institute and a Fellow of the Royal Society (pictured right). He spearheaded the development of mouse transgenics and their translational use, which provided the basis for developing canine monoclonal antibody therapies.
Allan said: "We are growing a world-class scientific team that will enable PetMedix to become a global leader in the development of novel monoclonal antibody therapies for the expanding animal health market. In the short lifetime of the company we have attracted huge talent in both our scientists and executives, and moved into the heart of the Cambridge biotech sphere with its excellent facilities and networking opportunities. The recent appointment of Dr. Fabian Kausche to the board marks our intent to become a global leader in animal health."
CEO, Dr. Tom Weaver added: "We have the people and the technology in place, and are champing at the bit to progress these therapies to reach the pets that could benefit. We know this technology has transformed the treatment and survival of human patients with a variety of conditions and we want to create the same paradigm shift in veterinary treatment options to improve welfare, quality of life and longevity for our dogs and cats."
PetMedix says it is interested in hearing from potential investment partners, and mergers and acquisitions. Contact Jolyon Martin via email: jolyon.martin@PetMedix.co.uk or telephone: +44 (0) 1223 734140,